Filament Health (OTCQB: FLHLF) and Jupiter Acquisition today announced that the SEC has declared effective the registration statement for their proposed merger. The SPAC called a Dec. 5 meeting at 10 a.m. Eastern for shareholders to vote on the business combination.
The deal values Filament at an equity value of approximately US$176 million and is expected to close by the end of 2023, subject to shareholder approvals and other closing condition.
Filament is a natural psychedelic drug development company focused on the treatment of substance use disorders.
Maxim Group is financial advisor to Filament. Fasken Martineau DuMoulin is Canadian legal advisor and Ellenoff Grossman & Schole is acting as U.S. legal advisor to Filament. Harper Grey is Canadian legal advisor and Greenberg Traurig is U.S. legal advisor to Jupiter. Read more.
